Drug discovery and development is a very challenging, expensive and time-consuming process.
The emerging role of physiologically-based pharmacokinetic/biopharmaceutics modeling in formulation development
Computer-based (in silico) modeling & simulation tools have been embraced in different fields of pharmaceutics for a variety of applications.
Pharmacokinetics of tulathromycin in pregnant ewes (Ovis aries) challenged with Campylobacter jejuni
The purpose of this study was to evaluate the pharmacokinetics of tulathromycin in the plasma and maternal and fetal tissues of pregnant ewes when administered within 24 hours of a...
Improving Dissolution Behavior and Oral Absorption of Drugs with pH-Dependent Solubility Using pH Modifiers: A Physiologically Realistic Mass Transport Analysis
Orally dosed drugs must dissolve in the gastrointestinal (GI) tract before being absorbed through the epithelial cell membrane.
PBPK Modeling as a Tool for Predicting and Understanding Intestinal Metabolism of Uridine 5′-Diphospho-Glucuronosyltransferase Substrates
Uridine 5′-diphospho-glucuronosyltransferases (UGTs) are expressed in the small intestines, but prediction of first-pass extraction from the related metabolism is not well studied.
Quantitative Systems Toxicology Modeling Predicts that Reduced Biliary Efflux Contributes to Tolvaptan Hepatotoxicity
Patients with autosomal dominant polycystic kidney disease (ADPKD) exhibit enhanced susceptibility to tolvaptan hepatotoxicity relative to other patient populations.
Computational pharmaceutics – A new paradigm of drug delivery
In recent decades pharmaceutics and drug delivery have become increasingly critical in the pharmaceutical industry due to longer time, higher cost, and less productivity of new molecular entities (NMEs).
Simulations Plus Reports Continued Success in Second Phase of AIDD Collaboration with Large Pharmaceutical Company
30% of synthesized molecules have measured activity which meet potency targets.
In Vitro-In Silico Tools for Streamlined Development of Acalabrutinib Amorphous Solid Dispersion Tablets
Amorphous solid dispersion (ASD) dosage forms can improve the oral bioavailability of poorly water-soluble drugs, enabling the commercialization of new chemical entities and improving the efficacy and patient...
IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study
IBI362 (LY3305677) is a novel weekly-dose glucagon-like peptide-1 and glucagon receptor dual agonist being developed for the treatment of obesity and type 2 diabetes.
Machine Learning in Drug Discovery: A Review
This review provides the feasible literature on drug discovery through ML tools and techniques that are enforced in every phase of drug development to accelerate the research....
August 2021 GastroPlus Newsletter
Coinciding with the milestone of our “silver anniversary” comes the news of the “passing of the torch”!
NMPA’s Center for Drug Evaluation Adds Licenses of GastroPlus®
Simulations Plus announced that China's Center for Drug Evaluation of the NMPA has added GastroPlus licenses for research aiding regulatory reviews
Real-world Considerations in Pharma for QSP Modeling
Quantitative systems pharmacology (QSP) modeling enables better drug development decisions through a more advanced understanding of the disease area of inter
3D-QSAR, molecular docking and in silico ADMET studies of propiophenone derivatives with anti-HIV-1 protease activity
HIV protease inhibitors are one of the most important agents for the treatment of HIV infection.
Absence of Association Between Abatacept Exposure and Initial Infection in Patients With Juvenile Idiopathic Arthritis
To assess the relationship between infection risk and abatacept (ABA) exposure levels in patients with polyarticular-course juvenile idiopathic arthritis (pJIA) following treatment with
Impact of Daridorexant, a Dual Orexin Receptor Antagonist, on Cardiac Repolarization Following Bedtime Dosing: Results from a Thorough QT Study Using Concentration-QT Analysis
Daridorexant is a new dual orexin receptor antagonist currently in late-stage clinical development for the treatment of insomnia.
Pharmacokinetic Profile of Pimavanserin in Patients With Dementia-Related Psychosis and Concomitant Acetylcholinesterase Inhibitor Use: Modeling Data From the Phase 3 HARMONY Study
Pimavanserin is a selective serotonin-modulating agent with inverse agonist/antagonist activity at the 5HT2A receptor, and to a lesser extent at...
Physiologically Based Pharmacokinetic Models Are Effective Support for Pediatric Drug Development
Pediatric drug development faces many difficulties. Traditionally, pediatric drug doses are simply calculated linearly based on the body weight, age, and body surface area of adults.